Company: IPHYF
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001598599-25-000042
Chunk: 202

Company: Innate Pharma SA
Filing Date: 2025-04-30
Form: 20-F
Item: Item 5
Chunk 202
---
 operation were nil for the year ended December 31, 2023 and 2022, respectively.

Cash flows from / (used in) financing activities

The Company's net cash flows used in financing activities for the year ended December 31, 2023 increased by €0.1 million to €2.0 million for the year ended December 31, 2023 as compared to net cash flows from financing activities of €1.8 million for the year ended December 31, 2022.

Loan repayments amounted to €2.4 million for the year ended December 31, 2023 as compared to €2.0 million for the year ended December 31, 2022.

In addition, net cash flows from financing activities related to Lumoxiti discontinued operations are nil for the year ended December 31, 2022 and 2021, respectively.

Funding requirements

Innate Pharma believes that its existing cash, cash equivalents, short-term investments and non-current financial assets, will enable it to fund its operations for at least the next 12 months. Innate has based this estimate on assumptions that may prove to be wrong, and the Company could use its capital resources sooner than it currently expects.

Until Innate can generate a sufficient amount of revenue from the sale of approved products, if ever, it expects to finance its operating activities through its existing liquidity and expected milestone payments from collaborators.

Innate's present and future funding requirements will depend on many factors, including, among other things:

• the size, progress, timing and completion of its clinical trials and preclinical studies for any current or future product candidates, including its lead product candidates, monalizumab and lacutamab;

• the number of potential new product candidates Innate identifies and decides to develop;

• costs associated with its payment obligations to third parties in connection with its development and potential commercialization of certain of its product candidates;

• costs associated with expanding its organization;

• the costs involved in filing patent applications and maintaining and enforcing patents or defending against claims of infringement raised by third parties;

• the time and costs involved in obtaining regulatory approval for its product candidates and any delays the Company may encounter as a result of evolving regulatory requirements or adverse results with respect to any of these product candidates;

• the amount of revenues, if any, Innate Pharma may derive either directly, or in the form of milestone or royalty payments from any future potential partnership agreements, from monalizumab, IPH5201,